C-MAP CARFILZOMIB MYELOMA ACCESS PROGRAM

Serial Number 85410049
606

Registration Progress

Application Filed
Aug 29, 2011
Under Examination
Sep 18, 2012
Approved for Publication
Jul 24, 2012
Published for Opposition
Jul 24, 2012
Registered

Trademark Image

C-MAP CARFILZOMIB MYELOMA ACCESS PROGRAM

Basic Information

Serial Number
85410049
Filing Date
August 29, 2011
Published for Opposition
July 24, 2012
Abandonment Date
April 21, 2014
Drawing Code
3000

Status Summary

Current Status
Inactive
Status Code
606
Status Date
Apr 21, 2014
Classes
044

Rights Holder

Onyx Pharmaceuticals, Inc.

03
Address
249 E. Grand Avenue
South San Francisco, CA 94080

Ownership History

Onyx Pharmaceuticals, Inc.

Original Applicant
03
South San Francisco, CA

Onyx Pharmaceuticals, Inc.

Owner at Publication
03
South San Francisco, CA

Legal Representation

Attorney
Richard M. LaBarge

USPTO Deadlines

All Deadlines Cleared

All 3 deadline(s) have been cleared by subsequent events. No active deadlines at this time.

Application History

36 events
Date Code Type Description Documents
Apr 21, 2014 ABN6 S ABANDONMENT - NO USE STATEMENT FILED Loading...
Apr 21, 2014 MAB6 O ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED Loading...
Feb 20, 2014 REAP I TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED Loading...
Feb 20, 2014 ARAA I ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED Loading...
Oct 19, 2013 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Oct 18, 2013 EX2G S SOU EXTENSION 2 GRANTED Loading...
Oct 11, 2013 AITU A CASE ASSIGNED TO INTENT TO USE PARALEGAL Loading...
Sep 17, 2013 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Sep 17, 2013 EXT2 S SOU EXTENSION 2 FILED Loading...
Mar 20, 2013 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Mar 18, 2013 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Mar 18, 2013 EXT1 S SOU EXTENSION 1 FILED Loading...
Mar 18, 2013 EX1G S SOU EXTENSION 1 GRANTED Loading...
Mar 15, 2013 TCCA I TEAS CHANGE OF CORRESPONDENCE RECEIVED Loading...
Sep 18, 2012 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Jul 24, 2012 PUBO A PUBLISHED FOR OPPOSITION Loading...
Jul 24, 2012 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Jul 4, 2012 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Jun 19, 2012 PREV O LAW OFFICE PUBLICATION REVIEW COMPLETED Loading...
Jun 13, 2012 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Jun 13, 2012 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Jun 12, 2012 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Jun 12, 2012 EAAU I TEAS AMENDMENT OF USE RECEIVED Loading...
Jun 9, 2012 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Jun 8, 2012 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Jun 8, 2012 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Dec 20, 2011 CNRT R NON-FINAL ACTION WRITTEN Loading...
Dec 20, 2011 GNRT F NON-FINAL ACTION E-MAILED Loading...
Dec 20, 2011 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Dec 15, 2011 DOCK D ASSIGNED TO EXAMINER Loading...
Sep 29, 2011 AMPX O PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED Loading...
Sep 22, 2011 ALIE A ASSIGNED TO LIE Loading...
Sep 21, 2011 PARI I TEAS VOLUNTARY AMENDMENT RECEIVED Loading...
Sep 2, 2011 MDSC O NOTICE OF DESIGN SEARCH CODE MAILED Loading...
Sep 1, 2011 NWAP I NEW APPLICATION ENTERED Loading...
Sep 1, 2011 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...

Detailed Classifications

Class 044
Charitable services, namely, patient assistance program to provide prescription drugs to low income patients
First Use Anywhere: 0
First Use in Commerce: 0

Additional Information

Design Mark
The mark consists of the words "C-MAP CARFILZOMIB MYELOMA ACCESS PROGRAM" with the word "C-MAP" in large letters above the words "CARFILZOMIB MYELOMA ACCESS PROGRAM" in smaller letters below "C-MAP". Behind the word "C-MAP" is a path that diminishes in size.
Color Claim
Color is not claimed as a feature of the mark.

Classification

International Classes
044

Disclaimers

The following terms have been disclaimed and are not claimed as part of the trademark:
General Disclaimer
"CARFILZOMIB MYELOMA ACCESS PROGRAM"